FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for JANUMET XR (sitagliptin and metformin hydrochloride) submitted by Merck Sharp & Dohme LLC, expanding its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• JANUMET XR (Sitagliptin and metformin hydrochloride)

Snippet

SUPPL AP for JANUMET XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE)